# PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer

> **NCT06933251** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Locally Advanced Rectal Cancer (LARC)

## Interventions

- **DRUG:** Neoadjuvant Chemoradiotherapy Combined with PD-1 inhibitor Immunotherapy and PCSK9 Inhibitor Therapy

## Key facts

- **NCT ID:** NCT06933251
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-20
- **Primary completion:** 2030-02-28
- **Final completion:** 2030-02-28
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06933251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06933251, "PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06933251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*